Learn Details of the Global RNAi Therapeutics Market Report by 2030

September 17, 2020
Ang001Foley

Roots Analysis has done a detailed study on RNAi Therapeutics Market (2nd Edition), 2019 – 2030: Focus on siRNA, miRNA, shRNA and DNA, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Key Inclusions

  • A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishment.
  • An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules. The trials were analyzed on the basis of various relevant parameters, such as registration year, current status, phase of development, type of RNAi molecule, regional distribution of clinical trials and enrolled patient population.
  • An in-depth analysis of the various patents that have been filed / granted related to RNAi therapeutics, since 2014. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
  • An analysis of the various partnerships pertaining to RNAi therapeutics, which have been established till August 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players.
  • An analysis of the investments made at various stages of development in companies engaged in this domain, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.
  • An analysis of the key promotional strategies that have been adopted by developers of marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.
  • A review of emerging technology platforms and delivery systems that are being used for targeted therapeutic delivery, featuring detailed profiles of technologies.
  • Detailed profiles of drug candidates that are in the advanced stages of development (phase II/III and above), including information on their current development status, mechanism of action, route of administration, affiliated delivery technology, dosage, recent clinical trial results along with information on their respective developers.
  • An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

Key therapeutic areas

  • Oncological disorders
  • Infectious diseases
  • Genetic disorders
  • Ophthalmic disorders
  • Hepatic disorders
  • Respiratory disorders

Type of RNAi molecule

  • siRNA
  • miRNA
  • shRNA
  • sshRNA
  • DNA

Route of administration

  • Subcutaneous
  • Intravenous
  • Intradermal
  • Intratumoral
  • Intravitreal
  • Oral
  • Intramuscular

Key geographical regions

  • North America
  • Europe
  • Asia Pacific and the Rest of the World

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html     

 

Article Tags:
Article Categories:
BUSINESS

Leave a Comment